Clopidogrelrezisztencia vizsgálata cerebrovascularis betegségben - Egyéves utánkövetés

Translated title of the contribution: Clopidogrel resistance in cerebrovascular disease - Results of one-year follow-up

L. Szapáry, Katalin Koltai, Antal Tibold, Andrea Fehér, Gábor Harang, Gabriella Pusch, G. Fehér

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: In an earlier study the authors reported short-term benefits of clopidogrel treatment in patients with cerebrovascular disease. Aim: The aim of the authors was to analyze findings during a 12-month follow-up period. Method: 100 patients with a history of acute stroke or transient ischaemic attack have been included in the study. The efficacy of the therapy was assessed 7 and 28 days as well as 3, 6 and 12 months after initiation of medical therapy. Patients were divided into two parts (clopidogrel responder and resistant) based on their initial laboratory findings. Risk profiles, medical therapy, laboratory parameters and vascular events were compared between the two patient groups. Results: After 7 days of treatment, clopidogrel seemed to be ineffective in 11 patients (11%). Strong, clinically significant correlations were found among blood pressure values, blood glucose and lipid parameters, serum C-reactive protein levels and platelet aggregation levels. An aggressive secondary preventive therapy resulted in a decrease of clopidogrel resistance and improvement in laboratory parameters. Patients who were clopidogrel resistant at baseline had significantly higher rate of vascular events compared to those who were clopidogrel responders (18.1 vs. 4.5%, p

Original languageHungarian
Pages (from-to)53-59
Number of pages7
JournalOrvosi Hetilap
Volume156
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

clopidogrel
Cerebrovascular Disorders
Blood Vessels
Therapeutics
Transient Ischemic Attack
Platelet Aggregation
C-Reactive Protein
Blood Glucose
Blood Proteins
Stroke

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clopidogrelrezisztencia vizsgálata cerebrovascularis betegségben - Egyéves utánkövetés. / Szapáry, L.; Koltai, Katalin; Tibold, Antal; Fehér, Andrea; Harang, Gábor; Pusch, Gabriella; Fehér, G.

In: Orvosi Hetilap, Vol. 156, No. 2, 01.01.2015, p. 53-59.

Research output: Contribution to journalArticle

Szapáry, L. ; Koltai, Katalin ; Tibold, Antal ; Fehér, Andrea ; Harang, Gábor ; Pusch, Gabriella ; Fehér, G. / Clopidogrelrezisztencia vizsgálata cerebrovascularis betegségben - Egyéves utánkövetés. In: Orvosi Hetilap. 2015 ; Vol. 156, No. 2. pp. 53-59.
@article{03bfc31dcab84b5db629b74ec5cfe51c,
title = "Clopidogrelrezisztencia vizsg{\'a}lata cerebrovascularis betegs{\'e}gben - Egy{\'e}ves ut{\'a}nk{\"o}vet{\'e}s",
abstract = "Introduction: In an earlier study the authors reported short-term benefits of clopidogrel treatment in patients with cerebrovascular disease. Aim: The aim of the authors was to analyze findings during a 12-month follow-up period. Method: 100 patients with a history of acute stroke or transient ischaemic attack have been included in the study. The efficacy of the therapy was assessed 7 and 28 days as well as 3, 6 and 12 months after initiation of medical therapy. Patients were divided into two parts (clopidogrel responder and resistant) based on their initial laboratory findings. Risk profiles, medical therapy, laboratory parameters and vascular events were compared between the two patient groups. Results: After 7 days of treatment, clopidogrel seemed to be ineffective in 11 patients (11{\%}). Strong, clinically significant correlations were found among blood pressure values, blood glucose and lipid parameters, serum C-reactive protein levels and platelet aggregation levels. An aggressive secondary preventive therapy resulted in a decrease of clopidogrel resistance and improvement in laboratory parameters. Patients who were clopidogrel resistant at baseline had significantly higher rate of vascular events compared to those who were clopidogrel responders (18.1 vs. 4.5{\%}, p",
keywords = "aggregometry, clinical outcome, clopidogrel, resistance, vascular prevention",
author = "L. Szap{\'a}ry and Katalin Koltai and Antal Tibold and Andrea Feh{\'e}r and G{\'a}bor Harang and Gabriella Pusch and G. Feh{\'e}r",
year = "2015",
month = "1",
day = "1",
doi = "10.1556/OH.2015.30057",
language = "Hungarian",
volume = "156",
pages = "53--59",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Clopidogrelrezisztencia vizsgálata cerebrovascularis betegségben - Egyéves utánkövetés

AU - Szapáry, L.

AU - Koltai, Katalin

AU - Tibold, Antal

AU - Fehér, Andrea

AU - Harang, Gábor

AU - Pusch, Gabriella

AU - Fehér, G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: In an earlier study the authors reported short-term benefits of clopidogrel treatment in patients with cerebrovascular disease. Aim: The aim of the authors was to analyze findings during a 12-month follow-up period. Method: 100 patients with a history of acute stroke or transient ischaemic attack have been included in the study. The efficacy of the therapy was assessed 7 and 28 days as well as 3, 6 and 12 months after initiation of medical therapy. Patients were divided into two parts (clopidogrel responder and resistant) based on their initial laboratory findings. Risk profiles, medical therapy, laboratory parameters and vascular events were compared between the two patient groups. Results: After 7 days of treatment, clopidogrel seemed to be ineffective in 11 patients (11%). Strong, clinically significant correlations were found among blood pressure values, blood glucose and lipid parameters, serum C-reactive protein levels and platelet aggregation levels. An aggressive secondary preventive therapy resulted in a decrease of clopidogrel resistance and improvement in laboratory parameters. Patients who were clopidogrel resistant at baseline had significantly higher rate of vascular events compared to those who were clopidogrel responders (18.1 vs. 4.5%, p

AB - Introduction: In an earlier study the authors reported short-term benefits of clopidogrel treatment in patients with cerebrovascular disease. Aim: The aim of the authors was to analyze findings during a 12-month follow-up period. Method: 100 patients with a history of acute stroke or transient ischaemic attack have been included in the study. The efficacy of the therapy was assessed 7 and 28 days as well as 3, 6 and 12 months after initiation of medical therapy. Patients were divided into two parts (clopidogrel responder and resistant) based on their initial laboratory findings. Risk profiles, medical therapy, laboratory parameters and vascular events were compared between the two patient groups. Results: After 7 days of treatment, clopidogrel seemed to be ineffective in 11 patients (11%). Strong, clinically significant correlations were found among blood pressure values, blood glucose and lipid parameters, serum C-reactive protein levels and platelet aggregation levels. An aggressive secondary preventive therapy resulted in a decrease of clopidogrel resistance and improvement in laboratory parameters. Patients who were clopidogrel resistant at baseline had significantly higher rate of vascular events compared to those who were clopidogrel responders (18.1 vs. 4.5%, p

KW - aggregometry

KW - clinical outcome

KW - clopidogrel

KW - resistance

KW - vascular prevention

UR - http://www.scopus.com/inward/record.url?scp=84920861219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920861219&partnerID=8YFLogxK

U2 - 10.1556/OH.2015.30057

DO - 10.1556/OH.2015.30057

M3 - Article

C2 - 25563682

AN - SCOPUS:84920861219

VL - 156

SP - 53

EP - 59

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 2

ER -